ESC 2019

33-43 of 43

Early and sustained vasodilation strategy fails to improve outcomes in acute HF
Early and sustained vasodilation strategy fails to improve outcomes in acute HF
ESC 2019
Early and sustained vasodilation strategy fails to improve outcomes in acute HF
- Prof. Christian Müller
Community-wide salt restriction reduces blood pressure and incidence of hypertension
Community-wide salt restriction reduces blood pressure and incidence of hypertension
ESC 2019
Community-wide salt restriction reduces blood pressure and incidence of hypertension
- Prof. Jaime Miranda
Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results
Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results
ESC 2019
Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results
- Prof. Stefanie Schüpke
Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes
Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes
ESC 2019
Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes
- Prof. John McMurray, MD
ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint
ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint
ESC 2019
ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint
- Scott Solomon, MD
DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI
DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI
ESC 2019
DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI
- Deepak Bhatt, MD
Major benefits with implementation of rapid rule-out pathway for MI
Major benefits with implementation of rapid rule-out pathway for MI
ESC 2019
Major benefits with implementation of rapid rule-out pathway for MI
- Prof. Nicholas Mills
A revolution in treatment of HFrEF with a SGLT2 inhibitor
A revolution in treatment of HFrEF with a SGLT2 inhibitor
ESC 2019
A revolution in treatment of HFrEF with a SGLT2 inhibitor
- Subodh Verma, MD, PhD
Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS
Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS
ESC 2019
Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS
- Prof. François Mach, MD
Decreased CV risk with an intervention targeting identified barriers to care
Decreased CV risk with an intervention targeting identified barriers to care
ESC 2019
Decreased CV risk with an intervention targeting identified barriers to care
- Prof. J-D Schwalm
Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition
Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition
ESC 2019
Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition
- Prof Kausik Ray

3/3

33-43 of 43

Title

Share on ReachMD